Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
200.17
-4.22 (-2.06%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Natera Employees
Natera had 6,140 employees as of December 31, 2025. The number of employees increased by 1,706 or 38.48% compared to the previous year.
Employees
6,140
Change (1Y)
1,706
Growth (1Y)
38.48%
Revenue / Employee
$375,588
Profits / Employee
-$33,902
Market Cap
28.37B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 6,140 | 1,706 | 38.48% |
| Dec 31, 2024 | 4,434 | 1,141 | 34.65% |
| Dec 31, 2023 | 3,293 | 275 | 9.11% |
| Dec 31, 2022 | 3,018 | 348 | 13.03% |
| Dec 31, 2021 | 2,670 | 855 | 47.11% |
| Dec 31, 2020 | 1,815 | 776 | 74.69% |
| Dec 31, 2019 | 1,039 | 64 | 6.56% |
| Dec 31, 2018 | 975 | 82 | 9.18% |
| Dec 31, 2017 | 893 | 41 | 4.81% |
| Dec 31, 2016 | 852 | 136 | 18.99% |
| Dec 31, 2015 | 716 | 42 | 6.23% |
| Dec 31, 2014 | 674 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| IQVIA Holdings | 93,000 |
| Labcorp Holdings | 71,000 |
| Quest Diagnostics | 57,000 |
| Mettler-Toledo International | 18,100 |
| Agilent Technologies | 18,100 |
| IDEXX Laboratories | 11,000 |
| Revvity | 11,000 |
| Illumina | 10,080 |
NTRA News
- 6 days ago - Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT - Business Wire
- 14 days ago - Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst - Benzinga
- 15 days ago - Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma - Business Wire
- 19 days ago - Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents - Business Wire
- 21 days ago - 20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera's Oncology Platform - Business Wire
- 4 weeks ago - Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery - Benzinga
- 4 weeks ago - SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery - Business Wire
- 6 weeks ago - Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers - Business Wire